Nicotinuric Acid

Nicotinuric Acid

SCHEMBL351962

O=C(O)CNC(=O)c1cccnc1

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.75
MEN1 O00255 4/20 0.63
KMT2A Q03164 4/20 0.63
NPC1 O15118 3/20 0.63
RAB9A P51151 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
HDAC1 Q13547 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
EPHX2 P34913 3/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
ALDH1A1 P00352 2/20 0.58
TSHR P16473 1/20 0.57
PLOD2 O00469 1/20 0.57
APP P05067 1/20 0.56
GAA P10253 1/20 0.56
HCAR3 P49019 1/20 0.56
HCAR2 Q8TDS4 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nicotinuric Acid SCHEMBL30183567 1.00 THRB (0.75) THRBMEN1KMT2ANPC1RAB9A
Nicotinuric Acid SCHEMBL9227412 0.98 THRB (0.73) THRBMEN1KMT2ANPC1RAB9A
Nicotinuric Acid SCHEMBL28292410 0.98 THRB (0.73) THRBMEN1KMT2ANPC1RAB9A
Nicotinuric Acid SCHEMBL28292397 0.98 THRB (0.73) THRBMEN1KMT2ANPC1RAB9A
Nicotinuric Acid SCHEMBL1219783 0.92 THRB (0.65) THRBMEN1KMT2ANPC1RAB9A
Nicotinuric Acid SCHEMBL15012491 0.91 THRB (0.63) THRBMEN1KMT2ANPC1RAB9A
Nicotinuric Acid SCHEMBL1219715 0.91 THRB (0.63) THRBMEN1KMT2ANPC1RAB9A
SCHEMBL22983350 0.89 NAMPT (0.66) THRBMEN1KMT2ANPC1RAB9A
Nicotinuric Acid SCHEMBL1219821 0.87 THRB (0.58) THRBMEN1KMT2ANPC1RAB9A
SCHEMBL3864600 0.86 THRB (0.75) THRBMEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4687829-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2026-02-11 EP claimed
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME OREAL (FR) 2025-12-18 US claimed
CN-120044159-A Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application 河北北方学院 2025-05-27 CN claimed
US-20250161201-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2025-05-22 US claimed
EP-4543408-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME L'OREAL (FR) 2025-04-30 EP claimed
EP-4479146-A1 COSMETIC COMPOSITION The Boots Company PLC (GB) 2024-12-25 EP claimed
CN-119110720-A Cosmetic composition 布茨公司 2024-12-10 CN claimed
WO-2024197798-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2024-10-03 WO claimed
WO-2023248248-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME L'ORÉAL (FR) 2023-12-28 WO claimed
WO-2023156070-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2023-08-24 WO claimed
WO-2007053773-A1 COMPOSITIONS AND METHODS USING NICOTINIC ACID FOR TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE HENDRIX CURT (US) 2007-05-10 WO claimed
EP-1633334-B1 TOPICAL ADMINISTRATION OF VASOACTIVE VITAMIN B3 COMPOUNDS FOR PROMOTING SLEEP PROCTER & GAMBLE (US) 2006-11-15 EP claimed
EP-1633334-A2 A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS THE PROCTER & GAMBLE COMPANY (US) 2006-03-15 EP claimed
WO-2005002554-A2 A METHOD OF PROMOTING SLEEP USING TOPICAL ADMINISTRATION OF VASOACTIVE AGENTS THE PROCTER & GAMBLE COMPANY (US) 2005-01-13 WO claimed
US-20040254202-A1 Method of promoting sleep using topical administration of vasoactive agents THE PROCTER & GAMBLE COMPANY 2004-12-16 US claimed
US-6818229-B1 ONCE A DAY DOSAGE WITHOUT CAUSING DRUG INDUCED HEPATIC TOXICITY; FDA ORANGE BOOK LISTED PATENT FOR NIACIN AND SIMVASTATIN KOS PHARMACEUTICALS, INC. 2004-11-16 US claimed
US-20040097482-A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications SCHERING CORPORATION 2004-05-20 US claimed
US-20020197289-A1 Compositions and methods for combating the appearance of ageing L'OREAL (FR) 2002-12-26 US claimed
US-6143770-A MIXTURES OF TOCOTRIENOL AND NICOTINIC ACID LIPOGENICS, INC. (US) 2000-11-07 US claimed
US-5430049-A Treating hyperproliferative disorders GAUT ZANE N (US) 1995-07-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020197289-A1 Compositions and methods for combating the appearance of ageing CYP24A1, CYP27B1, CYP2R1 THRB 2820/4885MEN1 4140/4885KMT2A 4139/4885
US-20250161201-A1 COSMETIC COMPOSITION CYP19A1, SHBG, HSD17B11 THRB 3106/4885MEN1 2548/4885KMT2A 3132/4885
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME TBCB, CCNB3, CYP24A1 THRB 494/4885MEN1 1459/4885KMT2A 3398/4885
US-20040097482-A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications CYP46A1, GPR119, APOB THRB 671/4885MEN1 325/4885KMT2A 3358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.